S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NYSE:CTLT

Catalent Stock Forecast, Price & News

$115.73
-1.09 (-0.93 %)
(As of 01/25/2021 05:06 PM ET)
Add
Compare
Today's Range
$114.25
Now: $115.73
$117.89
50-Day Range
$92.31
MA: $105.61
$119.83
52-Week Range
$31.04
Now: $115.73
$120.48
Volume830,037 shs
Average Volume1.00 million shs
Market Capitalization$19.06 billion
P/E Ratio73.71
Dividend YieldN/A
Beta1.5
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Catalent logo

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

237th out of 1,922 stocks

Pharmaceutical Preparations Industry

116th out of 771 stocks

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone732-537-6200
Employees13,900
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.09 billion
Cash Flow$3.76 per share
Book Value$18.71 per share

Profitability

Net Income$173 million

Miscellaneous

Market Cap$19.06 billion
Next Earnings Date2/2/2021 (Confirmed)
OptionableOptionable
$115.73
-1.09 (-0.93 %)
(As of 01/25/2021 05:06 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catalent (NYSE:CTLT) Frequently Asked Questions

How has Catalent's stock price been impacted by COVID-19 (Coronavirus)?

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CTLT shares have increased by 150.7% and is now trading at $115.44.
View which stocks have been most impacted by COVID-19
.

Is Catalent a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Catalent stock.
View analyst ratings for Catalent
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Catalent?

Wall Street analysts have given Catalent a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalent wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent CEO John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among Catalent's employees.

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Catalent
.

How can I listen to Catalent's earnings call?

Catalent will be holding an earnings conference call on Tuesday, February 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) announced its quarterly earnings results on Tuesday, November, 3rd. The company reported $0.43 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.37 by $0.06. The business had revenue of $845.70 million for the quarter, compared to the consensus estimate of $812.87 million. Catalent had a trailing twelve-month return on equity of 14.20% and a net margin of 9.25%. The business's revenue was up 27.2% on a year-over-year basis. During the same quarter last year, the business earned $0.26 EPS.
View Catalent's earnings history
.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2021 Pre-Market earnings guidance on Tuesday, November, 3rd. The company provided earnings per share guidance of 2.30-2.61 for the period, compared to the Thomson Reuters consensus estimate of $2.38. The company issued revenue guidance of $3.58-3.78 billion, compared to the consensus revenue estimate of $3.57 billion.

What price target have analysts set for CTLT?

9 brokerages have issued 12-month target prices for Catalent's stock. Their forecasts range from $75.00 to $130.00. On average, they expect Catalent's share price to reach $108.22 in the next twelve months. This suggests that the stock has a possible downside of 6.3%.
View analysts' price targets for Catalent
or view Wall Street analyst' top-rated stocks.

Are investors shorting Catalent?

Catalent saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 1,870,000 shares, an increase of 78.1% from the December 15th total of 1,050,000 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is presently 1.6 days.
View Catalent's Short Interest
.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Who are Catalent's key executives?

Catalent's management team includes the following people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 56, Pay $2.53M)
  • Mr. Alessandro Maselli, Pres & COO (Age 48, Pay $2.09M)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 48, Pay $988.4k)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $1.09M)
  • Ms. Karen A. Flynn, Pres of Biologics & Chief Commercial Officer (Age 57, Pay $665.37k)
  • Mr. Julien Meissonnier, VP & Chief Scientific Officer
  • Mr. Paul Surdez, VP of Investor Relations
  • Mr. Michael J. Grippo, Sr. VP of Strategy & Corp. Devel. (Age 51)
  • Mr. Ricardo Pravda, Sr. VP & Chief HR Officer (Age 49)
  • Dr. Aristippos Gennadios, Pres of Softgel & Oral Technologies (Age 54)

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.14%), Mountain Pacific Investment Advisers Inc. ID (0.13%), New York State Teachers Retirement System (0.10%), Vigilant Capital Management LLC (0.08%), McGuire Investment Group LLC (0.06%) and Buffington Mohr McNeal (0.05%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Scott Gunther, Steven L Fasman, Wetteny Joseph and William Downie.
View institutional ownership trends for Catalent
.

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Diversified Trust Co, Pacer Advisors Inc., State of Alaska Department of Revenue, Pendal Group Limited, OLD National Bancorp IN, Raymond James Trust N.A., and Mountain Pacific Investment Advisers Inc. ID. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Gregory T Lucier, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Ricci S Whitlow, Scott Gunther, Steven L Fasman, and Wetteny Joseph.
View insider buying and selling activity for Catalent
or view top insider-selling stocks.

Which major investors are buying Catalent stock?

CTLT stock was bought by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Peregrine Capital Management LLC, Buffington Mohr McNeal, Exchange Traded Concepts LLC, McGuire Investment Group LLC, KMG Fiduciary Partners LLC, IFM Investors Pty Ltd, and New York State Teachers Retirement System. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, and Peter L Buzy.
View insider buying and selling activity for Catalent
or or view top insider-buying stocks.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $115.44.

How big of a company is Catalent?

Catalent has a market capitalization of $19.01 billion and generates $3.09 billion in revenue each year. The company earns $173 million in net income (profit) each year or $1.88 on an earnings per share basis. Catalent employs 13,900 workers across the globe.

What is Catalent's official website?

The official website for Catalent is www.catalent.com.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.